Scientists launch major study to unlock secrets of deadly batten disease
NCT ID NCT03307304
First seen Jun 25, 2026 · Last updated Sep 09, 2026 · Updated 5 times
Summary
This study follows 300 people with CLN3 Batten disease, a rare genetic disorder that causes vision loss, seizures, and decline in thinking and movement. Researchers collect samples like blood and spinal fluid to find biological markers that could be used in future treatment trials. No experimental drug is given; the goal is to better understand the disease and prepare for future therapies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify biological markers that help design future treatments for Batten disease.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly improve symptoms, and findings may not lead to a therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2017
- Expected to finish
-
Dec 2050
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals with CLN3-Batten and family members who are interested in the study and have consented to enroll.
- Ages
-
1 week to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: For the Main and Sub-Studies, participants \> 1 week of age, of all genders, demographics, geographic locations, and disease severity will be recruited in order to obtain cross-sectional representation of CLN3-related conditions (Main and Sub-Studies) or all NCLs (Sub-Study B). Participants in the Main study will be followed at approximately yearly intervals to obtain longitudinal data. Participants in Sub-Study A may elect to send in medical records and samples only, or to come to the NIH for evaluations as outlined in Section 4. We anticipate that participants in Sub-Study B will be seen mostly at NCL/CLN3-related family conferences. Main Study: Individuals \> 1 week of age with a diagnosis of CLN3 or a CLN3-related/other NCL-type condition. Diagnosis determined by one of the following: 1. Two CLN3 or NCL condition-appropriate genetic mutations 2. One CLN3 mutation AND i) clinical presentation suggestive of CLN3, OR ii) characteristic electron microscopy (EM) findings (such as curvilinear body, fingerprint profile, granular osmiophilic deposits). Sub-Study A: Individuals \> 1 week of age with a diagnosis of CLN3 or CLN3-related/other NCL-type condition. Diagnosis determined by one of the following: 1. Two CLN3 or condition-appropriate genetic mutations 2. One CLN3 mutation AND i) clinical presentation suggestive of CLN3, OR ii) characteristic electron microscopy (EM) findings (such as curvilinear body, fingerprint profile, granular osmiophilic deposits). OR Individuals \> 1 month of age who have family member(s) diagnosed with CLN3 or CLN3-related/other NCL-type condition. Sub-Study B: Individuals \> 1 week of age with a clinical diagnosis of CLN3 or NCL. OR Individuals \> 1 month of age who have family member(s) diagnosed with CLN3 or NCL. EXCLUSION CRITERIA: Main Study: 1. Individuals who cannot travel to the NIH because of their medical condition. 2. Individuals who, in the opinion of the Investigator, are unable to comply with the protocol or have medical conditions that would potentially increase the risk of participation. 3. Females who are pregnant. Sub-Studies A and B: 1. Unaffected individuals \> 18 years of age who have cognitive impairments. 2. Individuals who, in the opinion of the Investigator, are unable to comply with the protocol or have medical conditions that would potentially increase the risk of participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Batten disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental gene therapy aims to halt rare fatal brain disease in children
- Thousands join fight against blindness by sharing their stories
- Experimental gene therapy aims to halt rare childhood brain disease
- Major study tracks rare brain diseases to unlock their secrets
- Experimental drug miglustat tested for rare batten disease
- Scientists track batten disease to unlock its secrets